{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:44:17Z","timestamp":1772034257559,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Chronic hepatitis C virus (HCV) infection is associated with dysregulation of glucose homeostasis, including insulin resistance (IR) and type 2 diabetes. However, independent risk factors associated with IR in chronic HCV-infected patients have not been detailly elucidated. Previous data regarding the impact of HCV elimination by direct-acting antiviral agents (DAAs) on glucose homeostasis is insufficient and controversial. This study aimed to analyze the independent factors associated with IR and to evaluate the changes in glucose homeostasis in chronic HCV-infected patients treated with DAAs therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We screened 704 patients with chronic HCV infection who underwent treatment with interferon-free DAAs. Patients\u2019 baseline characteristics, biochemical and virological data were collected. The outcome measurements were their IR and \u03b2-cell function assessed by the homeostasis model assessment (HOMA) method at baseline and 12-weeks post-treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>High IR (HOMA-IR \u2265 2.5) was observed in 35.1% of the patients. Multivariable logistic regression analysis revealed that body mass index (BMI) &amp;gt;25 kg\/m<jats:sup>2<\/jats:sup>, treatment experience, elevated baseline levels of alanine aminotransferase (ALT) and triglyceride, as well as Fibrosis-4 score &amp;gt;3.25 were independently associated with high IR. In patients who achieved sustained virological response (SVR), no significant change in mean HOMA-IR was observed from baseline to 12-weeks post-treatment (2.74 \u00b1 2.78 to 2.54 \u00b1 2.20, <jats:italic>p<\/jats:italic>\u00a0= 0.128). We observed a significant improvement in \u03b2-cell secretion stress from 121.0 \u00b1 110.1 to 107.6 \u00b1 93.0 (<jats:italic>p<\/jats:italic> = 0.015). Subgroup analysis revealed that SVR was associated with a significant reduction in mean HOMA-IR in patients with baseline HOMA-IR \u2265 2.5 (5.31 \u00b1 3.39 to 3.68 \u00b1 2.57, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), HCV genotype 1 (3.05 \u00b1 3.11 to 2.62 \u00b1 2.05, <jats:italic>p<\/jats:italic> = 0.027), and treatment experience (4.00 \u00b1 3.37 to 3.01 \u00b1 2.49, <jats:italic>p<\/jats:italic> = 0.039).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There were several independent factors associated with IR in patients with chronic HCV infection, including obesity, treatment experience, high serum ALT and triglyceride levels, as well as advanced hepatic fibrosis. After viral elimination by DAAs, we observed a significant reduction in mean HOMA-IR in patients with baseline high IR, HCV genotype 1, and treatment experience.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.799382","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T05:20:22Z","timestamp":1642051222000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Chun-Han","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Ying","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Tsung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hsien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Kai","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Jong","family":"Bair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.2951096","article-title":"Proinflammatory Cytokines, Insulin Resistance, and Insulin Secretion in Chronic Hepatitis C Patients: A Case-Control Study","volume":"29","author":"Lecube","year":"2006","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.056","article-title":"Hepatitis C Virus Infection and Diabetes: Direct Involvement of the Virus in the Development of Insulin Resistance","volume":"126","author":"Shintani","year":"2004","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-8-200010170-00018","article-title":"An Association Between Hepatitis C Virus Infection and Type 2 Diabetes Mellitus: What Is the Connection","volume":"133","author":"Alexander","year":"2000","journal-title":"Ann Internal Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50291","article-title":"Hepatitis C Virus Infection and Incident Type 2 Diabetes","volume":"38","author":"Mehta","year":"2003","journal-title":"Hepatology (Baltimore Md)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.08.006","article-title":"Hepatitis C Infection and Risk of Diabetes: A Systematic Review and Meta-Analysis","volume":"49","author":"White","year":"2008","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i9.1697","article-title":"Diabetes Mellitus, Insulin Resistance and Hepatitis C Virus Infection: A Contemporary Review","volume":"23","author":"Desbois","year":"2017","journal-title":"World J Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835612ce","article-title":"Insulin Resistance Is Associated With Progression to Hepatic Fibrosis in a Cohort of HIV\/hepatitis C Virus-Coinfected Patients","volume":"26","author":"Hull","year":"2012","journal-title":"AIDS (London England)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290632","article-title":"Insulin and Insulin-Like Growth Factor-1 Stimulate Proliferation and Type I Collagen Accumulation by Human Hepatic Stellate Cells: Differential Effects on Signal Transduction Pathways","volume":"29","author":"Svegliati-Baroni","year":"1999","journal-title":"Hepatology (Baltimore Md)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.28055","article-title":"High Glucose and Hyperinsulinemia Stimulate Connective Tissue Growth Factor Expression: A Potential Mechanism Involved in Progression to Fibrosis in Nonalcoholic Steatohepatitis","volume":"34","author":"Paradis","year":"2001","journal-title":"Hepatology (Baltimore Md)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01408.x","article-title":"The Impact of Diabetes Mellitus on Fibrosis Progression in Patients Transplanted for Hepatitis C","volume":"6","author":"Foxton","year":"2006","journal-title":"Am J Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26087","article-title":"Effect of Type 2 Diabetes on Risk for Malignancies Includes Hepatocellular Carcinoma in Chronic Hepatitis C","volume":"57","author":"Arase","year":"2013","journal-title":"Hepatology (Baltimore Md)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2015.12.002","article-title":"Impaired Glucose Metabolism Increases Risk of Hepatic Decompensation and Death in Patients With Compensated Hepatitis C Virus-Related Cirrhosis","volume":"48","author":"Calzadilla-Bertot","year":"2016","journal-title":"Dig Liver Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i11.2888","article-title":"Interaction Between Hepatitis C Virus and Metabolic Factors","volume":"20","author":"Kawaguchi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01672-07","article-title":"Hepatitis C Virus Core Protein Upregulates Serine Phosphorylation of Insulin Receptor Substrate-1 and Impairs the Downstream Akt\/Protein Kinase B Signaling Pathway for Insulin Resistance","volume":"82","author":"Banerjee","year":"2008","journal-title":"J Virol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.22072","article-title":"Effects of Hepatitis C Virus on Suppressor of Cytokine Signaling mRNA Levels: Comparison Between Different Genotypes and Core Protein Sequence Analysis","volume":"83","author":"Pascarella","year":"2011","journal-title":"J Med Virol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2005.12.003","article-title":"The Protein Phosphatase 2A Represents a Novel Cellular Target for Hepatitis C Virus NS5A Protein","volume":"88","author":"Georgopoulou","year":"2006","journal-title":"Biochimie"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00585-12","article-title":"Regulation of Hepatitis C Virus Replication by Nuclear Translocation of Nonstructural 5A Protein and Transcriptional Activation of Host Genes","volume":"87","author":"Maqbool","year":"2013","journal-title":"J\u00a0Virol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21634","article-title":"The Hepatitis C Virus Core Protein of Genotypes 3a and 1b Downregulates Insulin Receptor Substrate 1 Through Genotype-Specific Mechanisms","volume":"45","author":"Pazienza","year":"2007","journal-title":"Hepatology (Baltimore Md)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01626.x","article-title":"High Hepatitis C Viral Load Is Associated With Insulin Resistance in Patients With Chronic Hepatitis C","volume":"28","author":"Hsu","year":"2008","journal-title":"Liver Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04094.x","article-title":"Serum HCV RNA Levels and HCV Genotype do Not Affect Insulin Resistance in Nondiabetic Patients With Chronic Hepatitis C: A Multicentre Study","volume":"30","author":"Tsochatzis","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.01038.x","article-title":"Clearance of HCV Improves Insulin Resistance, Beta-Cell Function, and Hepatic Expression of Insulin Receptor Substrate 1 and 2","volume":"102","author":"Kawaguchi","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.01.022","article-title":"Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial","volume":"8","author":"Delgado-Borrego","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02545.x","article-title":"Pegylated Interferon Plus Ribavirin Therapy Improves Pancreatic \u03b2-Cell Function in Chronic Hepatitis C Patients","volume":"31","author":"Huang","year":"2011","journal-title":"Liver Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.11.022","article-title":"Effect of Sustained Virological Response to Treatment on the Incidence of Abnormal Glucose Values in Chronic Hepatitis C","volume":"48","author":"Romero-G\u00f3mez","year":"2008","journal-title":"J Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22703","article-title":"Sustained Virological Response Reduces Incidence of Onset of Type 2 Diabetes in Chronic Hepatitis C","volume":"49","author":"Arase","year":"2009","journal-title":"Hepatology (Baltimore Md)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/cells8030252","article-title":"Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid But Not Glucose Parameters","volume":"8","author":"Doyle","year":"2019","journal-title":"Cells"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4065\/75.4.355","article-title":"Increased Risk of Type 2 Diabetes in Noncirrhotic Patients With Chronic Hepatitis C Virus Infection","volume":"75","author":"Knobler","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.11.010","article-title":"Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis","volume":"134","author":"Moucari","year":"2008","journal-title":"Gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/cells8101249","article-title":"Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis","volume":"8","author":"Khatun","year":"2019","journal-title":"Cells"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis\u2013a Common Pathway to Organ Injury and Failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(03)00456-2","article-title":"Fibrogenic Impact of High Serum Glucose in Chronic Hepatitis C","volume":"39","author":"Ratziu","year":"2003","journal-title":"J Hepatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.236158","article-title":"Viral Clearance Is Associated With Improved Insulin Resistance in Genotype 1 Chronic Hepatitis C But Not Genotype 2\/3","volume":"61","author":"Thompson","year":"2012","journal-title":"Gut"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22251","article-title":"Increased Risk of Hepatocellular Carcinoma Among Patients With Hepatitis C Cirrhosis and Diabetes Mellitus","volume":"47","author":"Veldt","year":"2008","journal-title":"Hepatology (Baltimore Md)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.073","article-title":"Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B\/C Infection: A Follow-Up Study in Taiwan","volume":"135","author":"Chen","year":"2008","journal-title":"Gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32111-1","article-title":"Clinical Outcomes in Patients With Chronic Hepatitis C After Direct-Acting Antiviral Treatment: A Prospective Cohort Study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet (London England)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12967-019-2033-x","article-title":"Incidence and Risk Factors of Early HCC Occurrence in HCV Patients Treated With Direct Acting Antivirals: A Prospective Multicentre Study","volume":"17","author":"Rinaldi","year":"2019","journal-title":"J\u00a0Trans Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14168","article-title":"Reduced Incidence of Type 2 Diabetes in Patients With Chronic Hepatitis C Virus Infection Cleared by Direct-Acting Antiviral Therapy: A Prospective Study","volume":"22","author":"Adinolfi","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0163644","DOI":"10.1371\/journal.pone.0163644","article-title":"Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration During Hepatitis C Interferon-Free Treatment","volume":"11","author":"Hashimoto","year":"2016","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","article-title":"Worsening of Serum Lipid Profile After Direct Acting Antiviral Treatment","volume":"17","author":"Gitto","year":"2018","journal-title":"Ann Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2020.01.010","article-title":"Impact of Hepatitis C Virus Clearance by Direct-Acting Antiviral Treatment on the Incidence of Major Cardiovascular Events: A Prospective Multicentre Study","volume":"296","author":"Adinolfi","year":"2020","journal-title":"Atherosclerosis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.04.016","article-title":"Impact of Direct Acting Antivirals (DAAs) on Cardiovascular Events in HCV Cohort With Pre-Diabetes","volume":"31","author":"Sasso","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.799382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T05:20:23Z","timestamp":1642051223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.799382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":41,"alternative-id":["10.3389\/fendo.2021.799382"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.799382","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"article-number":"799382"}}